FACTORS ASSOCIATED WITH BLEEDING EVENTS IN PATIENTS ON RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION: A REAL WORLD EXPERIENCE

被引：1
|
作者：
Akhtar, Tauseef [1 ]
Mattumpuram, Jishanth [1 ]
Fugar, Setri [1 ]
Ranka, Sagar [1 ]
Fratti, Juan Del Cid [1 ]
Mann, Hashim [1 ]
Uprety, Alok [1 ]
Putta, Aakash [1 ]
Golzar, Yasmeen [1 ]
机构：
[1] John H Stroger Hosp Cook Cty, Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
D O I：
10.1016/S0735-1097(19)31079-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1267-270
引用
收藏
页码：471 / 471
页数：1
相关论文
共 50 条
  • [31] Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England
    Bakhai, Ameet
    Petri, Hans
    Vahidnia, Farnaz
    Wolf, Cyrill
    Ding, Yingjie
    Foskett, Nadia
    Sculpher, Mark
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2021, 27 (01) : 119 - 133
  • [32] Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation
    Kim, Yun Gi
    Choi, Jong-Il
    Boo, Ki Yung
    Kim, Do Young
    Hong, Yeji
    Kim, Min Sun
    Lee, Kwang-No
    Shim, Jaemin
    Kim, Jin Seok
    Kim, Young-Hoon
    [J]. CLINICAL CARDIOLOGY, 2020, 43 (01) : 78 - 85
  • [33] Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
    Berger, Jeffrey S.
    Laliberte, Francois
    Kharat, Akshay
    Lejeune, Dominique
    Moore, Kenneth Todd
    Jung, Young
    Lefebvre, Patrick
    Ashton, Veronica
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (06) : 881 - 890
  • [34] Effects of rivaroxaban on coagulation tests in patients with non-valvular atrial fibrillation under real-life conditions
    Silva, V. M.
    Scanavacca, M.
    Darrieux, F.
    Cavalheiro-Filho, C.
    Strunz, C. C.
    [J]. THROMBOSIS RESEARCH, 2017, 154 : 26 - 27
  • [35] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    [J]. CIRCULATION, 2014, 130
  • [36] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763
  • [37] REAL- WORLD EFFECTIVENESS AND SAFETY OF RIVAROXABAN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) AND VENOUS THROMBOEMBOLISM (VTE) IN SAUDI ARABIA
    Alosaimi, H.
    Alqahtani, S.
    Balkhi, B.
    Asiri, Y.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S149 - S149
  • [38] A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
    Alosaimi, Hind M.
    Alqahtani, Saeed
    Balkhi, Bander
    Alqahtani, Mishari
    Alzamil, Faisal
    Alhossan, Abdulaziz
    Alqahtany, Fatmah S.
    Alharbi, Abdullah A.
    Alqahtani, Nawaf Abdullah
    Albackr, Hanan
    Elgohary, Ghada
    Algahtani, Farjah H.
    [J]. PEERJ, 2022, 10
  • [39] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    [J]. REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [40] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
12345